Tefibazumab: Difference between revisions

Revision as of 23:06, 13 November 2011 editThe chemistds (talk \| contribs)Extended confirmed users5,761 edits No ChemSpider ID for this record← Previous edit		Revision as of 23:17, 13 November 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology...Next edit →
Line 1:		Line 1:
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 450331798		\| verifiedrevid = 450331798
	\| image =		\| image =
Line 38:		Line 39:
	\| KEGG_Ref = {{keggcite\|correct\|kegg}}		\| KEGG_Ref = {{keggcite\|correct\|kegg}}
	\| KEGG = D06054		\| KEGG = D06054
			\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
	\| ChemSpiderID = NA		\| ChemSpiderID = NA

Revision as of 23:17, 13 November 2011

Pharmaceutical compound

Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis and of methicillin-resistant S. aureus.

It was developed by Inhibitex.

Clinical trial number NCT00198289 at ClinicalTrials.gov
PMID 18221183
John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.